These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 18793670)
1. Carnitine in metabolic disease: potential for pharmacological intervention. Arduini A; Bonomini M; Savica V; Amato A; Zammit V Pharmacol Ther; 2008 Nov; 120(2):149-56. PubMed ID: 18793670 [TBL] [Abstract][Full Text] [Related]
2. Carnitine replacement in end-stage renal disease and hemodialysis. Calvani M; Benatti P; Mancinelli A; D'Iddio S; Giordano V; Koverech A; Amato A; Brass EP Ann N Y Acad Sci; 2004 Nov; 1033():52-66. PubMed ID: 15591003 [TBL] [Abstract][Full Text] [Related]
3. Pharmacological use of L-carnitine in uremic anemia: has its full potential been exploited? Bonomini M; Zammit V; Pusey CD; De Vecchi A; Arduini A Pharmacol Res; 2011 Mar; 63(3):157-64. PubMed ID: 21138768 [TBL] [Abstract][Full Text] [Related]
5. The effect of L-carnitine on insulin resistance in hemodialysed patients with chronic renal failure. Günal AI; Celiker H; Dönder E; Günal SY J Nephrol; 1999; 12(1):38-40. PubMed ID: 10203002 [TBL] [Abstract][Full Text] [Related]
6. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. Brandi L Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159 [TBL] [Abstract][Full Text] [Related]
7. Advances in carnitine in chronic uremia. Guarnieri G; Biolo G; Vinci P; Massolino B; Barazzoni R J Ren Nutr; 2007 Jan; 17(1):23-9. PubMed ID: 17198928 [TBL] [Abstract][Full Text] [Related]
8. Insulin action on glucose and protein metabolism during L-carnitine supplementation in maintenance haemodialysis patients. Biolo G; Stulle M; Bianco F; Mengozzi G; Barazzoni R; Vasile A; Panzetta G; Guarnieri G Nephrol Dial Transplant; 2008 Mar; 23(3):991-7. PubMed ID: 18045815 [TBL] [Abstract][Full Text] [Related]
13. L-carnitine supplementation in dialysis: treatment in quest of disease. Wasserstein AG Semin Dial; 2013; 26(1):11-5. PubMed ID: 23173999 [TBL] [Abstract][Full Text] [Related]
14. Homocysteine as a risk factor for cardiovascular disease in patients treated by dialysis: a meta-analysis. Heinz J; Kropf S; Luley C; Dierkes J Am J Kidney Dis; 2009 Sep; 54(3):478-89. PubMed ID: 19359080 [TBL] [Abstract][Full Text] [Related]
15. Clinical management of dialysis-related carnitine deficiency: three case studies. Lindberg J; Sadler R; Slowik M Nephrol News Issues; 2003 Apr; 17(5):73-6, 78. PubMed ID: 12715628 [TBL] [Abstract][Full Text] [Related]
16. L-carnitine supplementation in the dialysis population: are Australian patients missing out? Reuter SE; Faull RJ; Evans AM Nephrology (Carlton); 2008 Feb; 13(1):3-16. PubMed ID: 18199095 [TBL] [Abstract][Full Text] [Related]
17. L-carnitine supplementation in dialysis patients: does the evidence justify its use? Steinman TI Semin Dial; 2005; 18(1):1-2. PubMed ID: 15663752 [TBL] [Abstract][Full Text] [Related]
18. [Electrolyte and acid-base balance disorders in advanced chronic kidney disease]. Alcázar Arroyo R Nefrologia; 2008; 28 Suppl 3():87-93. PubMed ID: 19018744 [TBL] [Abstract][Full Text] [Related]
19. [Renal replacement therapy by hemodialysis: an overview]. Jacobs C Nephrol Ther; 2009 Jul; 5(4):306-12. PubMed ID: 19481513 [TBL] [Abstract][Full Text] [Related]
20. Effect of hemodialysis session on the dynamics of carnitine ester profile changes in L-carnitine pretreated end-stage renal disease patients. Csiky B; Bene J; Wittmann I; Sulyok E; Melegh B Int Urol Nephrol; 2013 Jun; 45(3):847-55. PubMed ID: 22684763 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]